JP2024544499A - 遺伝子工学的改変により得られた、分泌能と凝固活性を向上させた組換えヒト第viii因子 - Google Patents
遺伝子工学的改変により得られた、分泌能と凝固活性を向上させた組換えヒト第viii因子 Download PDFInfo
- Publication number
- JP2024544499A JP2024544499A JP2024526888A JP2024526888A JP2024544499A JP 2024544499 A JP2024544499 A JP 2024544499A JP 2024526888 A JP2024526888 A JP 2024526888A JP 2024526888 A JP2024526888 A JP 2024526888A JP 2024544499 A JP2024544499 A JP 2024544499A
- Authority
- JP
- Japan
- Prior art keywords
- fviii
- hfviii
- factor viii
- human factor
- domain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/745—Blood coagulation or fibrinolysis factors
- C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Virology (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- General Chemical & Material Sciences (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2021133004 | 2021-11-25 | ||
| CNPCT/CN2021/133004 | 2021-11-25 | ||
| PCT/CN2022/075976 WO2023092864A1 (en) | 2021-11-25 | 2022-02-11 | Engineered human fviii with enhanced secretion ability and clotting activity |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024544499A true JP2024544499A (ja) | 2024-12-03 |
| JP2024544499A5 JP2024544499A5 (cg-RX-API-DMAC7.html) | 2025-02-10 |
Family
ID=84487686
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024526888A Pending JP2024544499A (ja) | 2021-11-25 | 2022-02-11 | 遺伝子工学的改変により得られた、分泌能と凝固活性を向上させた組換えヒト第viii因子 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20240254197A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4211153A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2024544499A (cg-RX-API-DMAC7.html) |
| CN (3) | CN118638211A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2023092864A1 (cg-RX-API-DMAC7.html) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014209942A1 (en) * | 2013-06-24 | 2014-12-31 | Weidong Xiao | Mutant factor viii compositions and methods |
| WO2016123200A1 (en) * | 2015-01-30 | 2016-08-04 | Emory University | Factor viii proteins having ancestral sequences, expression vectors, and uses related thereto |
| JP2020519272A (ja) * | 2017-05-09 | 2020-07-02 | エモリー ユニバーシティー | 凝固因子変異体及びその使用 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1502921A1 (en) * | 2003-07-29 | 2005-02-02 | ZLB Behring GmbH | Recombinant mutated human factor VIII (FVIII) with improved stability |
| EP1985631A1 (en) * | 2007-04-20 | 2008-10-29 | LFB Biotechnologies | Demannosylated recombinant factor VIII for the treatment of patients with hemophiila A |
| WO2013123457A1 (en) * | 2012-02-15 | 2013-08-22 | Biogen Idec Ma Inc. | Recombinant factor viii proteins |
| US20160311885A1 (en) * | 2013-08-14 | 2016-10-27 | Biogen Ma Inc. | Recombinant factor viii proteins |
| CN108884145B (zh) * | 2015-11-13 | 2023-08-22 | 武田药品工业株式会社 | 用于血友病a的基因治疗的具有增加的表达的编码重组fviii变体的病毒载体 |
| KR102219859B1 (ko) * | 2016-06-24 | 2021-02-25 | 재단법인 목암생명과학연구소 | 재조합 단쇄 fviii 및 그 화학 접합물 |
| TWI851647B (zh) * | 2019-01-16 | 2024-08-11 | 日商武田藥品工業股份有限公司 | 用於a型血友病基因治療之編碼表現增加之重組fviii變異體的病毒載體 |
| WO2022165390A1 (en) * | 2021-01-29 | 2022-08-04 | Expression Therapeutics, Llc | Nucleic acid and amino acid sequences encoding high-level expressor factor viii polypeptides and methods of use |
-
2022
- 2022-02-11 CN CN202410604831.3A patent/CN118638211A/zh active Pending
- 2022-02-11 EP EP22726380.3A patent/EP4211153A4/en active Pending
- 2022-02-11 WO PCT/CN2022/075976 patent/WO2023092864A1/en not_active Ceased
- 2022-02-11 US US17/774,450 patent/US20240254197A1/en active Pending
- 2022-02-11 JP JP2024526888A patent/JP2024544499A/ja active Pending
- 2022-02-11 CN CN202410604829.6A patent/CN118546234A/zh active Pending
- 2022-02-11 CN CN202280001407.9A patent/CN116710554B/zh active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014209942A1 (en) * | 2013-06-24 | 2014-12-31 | Weidong Xiao | Mutant factor viii compositions and methods |
| WO2016123200A1 (en) * | 2015-01-30 | 2016-08-04 | Emory University | Factor viii proteins having ancestral sequences, expression vectors, and uses related thereto |
| JP2020519272A (ja) * | 2017-05-09 | 2020-07-02 | エモリー ユニバーシティー | 凝固因子変異体及びその使用 |
Non-Patent Citations (4)
| Title |
|---|
| "Accession No. XP_023615755", NCBI [ONLINE], JPN6025053010, 2018, ISSN: 0005767417 * |
| "Accession No. XP_036160738", NCBI [ONLINE], JPN6025053011, 2020, ISSN: 0005767418 * |
| BRITISH JOURNAL OF HAEMATOLOGY, vol. 131, JPN6026016987, 2005, pages 109 - 117, ISSN: 0005856731 * |
| 東医大誌, vol. 64, no. 4, JPN6026016986, 2006, pages 380 - 387, ISSN: 0005856730 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN118546234A (zh) | 2024-08-27 |
| CN116710554B (zh) | 2024-06-07 |
| TW202321290A (zh) | 2023-06-01 |
| WO2023092864A1 (en) | 2023-06-01 |
| CN118638211A (zh) | 2024-09-13 |
| US20240254197A1 (en) | 2024-08-01 |
| EP4211153A4 (en) | 2023-11-01 |
| CN116710554A (zh) | 2023-09-05 |
| EP4211153A1 (en) | 2023-07-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20240207392A1 (en) | Epstein-barr virus mrna vaccines | |
| US20240226277A1 (en) | Influenza-coronavirus combination vaccines | |
| CN112225793B (zh) | 一种溶酶体靶向肽及其融合蛋白、携带融合蛋白编码序列的腺相关病毒载体及其应用 | |
| TW202310880A (zh) | 靶向肌肉之基因療法之功效改進 | |
| CN111718947B (zh) | 用于治疗ⅲa或ⅲb型粘多糖贮积症的腺相关病毒载体及用途 | |
| EP4069849B1 (en) | Liver-specific promoter and application thereof | |
| CN114929872A (zh) | 用nadh脱氢酶蛋白治疗莱伯遗传性视神经病变的组合物和方法 | |
| TW202221126A (zh) | 用於鑑別及特徵化指環病毒之方法及其用途 | |
| WO2024230802A1 (en) | Engineered liver-specific core promoters and their applications | |
| WO2026017126A1 (zh) | 一种人工设计的新型nrg-1在疾病治疗中的应用 | |
| CN116710554B (zh) | 基因工程改造获得的分泌能力和凝血活性增强的人类八因子 | |
| RU2852567C2 (ru) | Сконструированный полипептид человеческого фактора VIII (hFVIII) с повышенной коагулирующей активностью, фрагмент выделенной нуклеиновой кислоты, вектор экспрессии (варианты), фармацевтическая композиция для лечения гемофилии A и способ ее лечения | |
| US20240277834A1 (en) | Nucleic acid molecules | |
| BR112019017444A2 (pt) | regulação da expressão gênica por acessibilidade mediada por aptâmero de sinais de poliadenilação | |
| US20250121096A1 (en) | Engineered liver-specific enhancers and their applications | |
| TWI893802B (zh) | 工程化的肝臟特異性增強子、核心啟動子及其應用 | |
| HK40120431A (en) | Engineered liver-specific core promoters and their applications | |
| CN115838725B (zh) | 在哺乳动物心脏中特异性启动基因的启动子序列及其应用 | |
| CN119685289A (zh) | 一种用于调控CaMKII-δ亚型选择性表达的单碱基编辑系统 | |
| CN121472228A (zh) | 3’ utr元件、重组载体及其制备方法和应用 | |
| CN112695032A (zh) | 一种启动子pLRRK2及其应用 | |
| CN120242072A (zh) | 一种治疗代谢性疾病的mRNA、药物组合物及应用 | |
| CN117683143A (zh) | 一种编码血管内皮生长因子A融合蛋白的mRNA分子及其应用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20250131 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20250131 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20251226 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20260106 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20260406 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20260512 |